CN102948413A - Hepatic stem cell preserving solution and applications of hepatic stem cell preserving solution - Google Patents
Hepatic stem cell preserving solution and applications of hepatic stem cell preserving solution Download PDFInfo
- Publication number
- CN102948413A CN102948413A CN2011102515988A CN201110251598A CN102948413A CN 102948413 A CN102948413 A CN 102948413A CN 2011102515988 A CN2011102515988 A CN 2011102515988A CN 201110251598 A CN201110251598 A CN 201110251598A CN 102948413 A CN102948413 A CN 102948413A
- Authority
- CN
- China
- Prior art keywords
- stem cells
- liver stem
- stem cell
- liquid
- hepatic stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses hepatic stem cell preserving solution and applications of the hepatic stem cell preserving solution. The hepatic stem cell preserving solution provided by the invention is prepared by fixing the volume of injection solution including 0.1 to 1g of human albumin, 2.60 to 4.97g of sodium chloride, 2.48 to 4.74g of sodium gluconate, 1.82 to 3.40g of sodium acetate, 0.18 to 0.35g of potassium chloride, 0.15 to 0.28g of magnesium chloride, and 0.4 to 0.7mL of heparin calcium based on effective dose by water to be reach to 100mL. The hepatic stem cell preserving solution provided by the invention is used for storing hepatic stem cells, and the survival rate of the hepatic stem cell is more than 85% and even more than 95% within 12 hours. The cell suspension which is obtained by floating the hepatic stem cells on the hepatic stem cell preserving solution can be used as the medicine for treating diabetes mellitus, and has the characteristics of being high in stability, good in curative effect, high in safety, being without toxic or side effect, convenient to store and transport, applicable to massive clinical use, and broad in application prospect. The hepatic stem cell preserving solution brings good news for diabetic patients, and provides a new way for clinical stem cell use.
Description
Technical field
The present invention relates to a kind of liver stem cells and preserve liquid and application thereof.
Background technology
" diabetes " are the diseases of the easy overheap of glucose in a kind of blood.Give its another name " reticent killer " (Silent Killer) abroad, particularly " adult diabetes mellitus ", it is high especially that a middle-aged person more than 40 years old catches rate, in Japan, account for 10% in the population more than 40 years old, " diabetes " patient is namely just arranged in the middle of ten people.In case suffer from " diabetes ", will reduce 10 years more than life-span, and contingent complication spread all over whole body.Itself also brings unusual misery to the people " diabetes ", allows the people usually think that dry wants to drink water, and because diuresis is repeatedly waken up midnight, still feels hunger although eaten many foods, lose weight, drowsiness etc., always allow the people feel the whole body where locate not in harmony.By the time in the time of can feeling the obvious situation in somewhere, the state of an illness of " diabetes " has developed into to a certain degree.And fearful complication is also developing at whole body thereupon stealthily everywhere.
Liver stem cells is a kind of cell with two-way differentiation potential that derives from the narrow crack of liver Herring and stones in intrahepatic bile duct, can be divided into hepatic parenchymal cells and bile duct epithelial cell.The cytoplasm of this cell is few, has oval cell nuclear, so * title elliptocyte (Oval).In normal situation, this ovum garden cell is static, and quantity seldom.Seriously reach in the continuation hepatic injury liver cell, hepatocellular multiplication capacity weakens, this liver stem cells subgroup that the is called elliptocyte propagation that is activated.Liver stem cells is effective to diabetes, but has individual difference, and the somebody cuts out insulin, somebody's insulin decrement after getting involved liver stem cells.
Although liver stem cells can form insulin secretory cell by number of ways, liver stem cells turns the machine-processed not clear of differentiation to pancreatic cell.Someone thinks that possibility liver, pancreas and small intestine derive from endoblastic cell jointly, perhaps have so adjacent zone, in growth course or under certain incentive condition, this regional cell can or move back differentiation by reprogrammed and turn and be differentiated to form the phenotype that is different from normal structure fully.This does not get rid of another kind of possibility: have the stem cell of a small set of multipotency in the adult tissue, they have to the ability of a plurality of systems differentiation.
Summary of the invention
The purpose of this invention is to provide a kind of liver stem cells and preserve liquid and application thereof.
Liver stem cells provided by the invention is preserved liquid, is that human serum albumin, 2.60-4.97g sodium chloride, 2.48-4.74g gluconic acid sodium salt, 1.82-3.40g sodium acetate, 0.18-0.35g potassium chloride, 0.15-0.28g magnesium chloride and 0.4-0.7mL heparin calcium inj water with the 0.1-1g effective dose is settled to 100mL and obtains.
Liver stem cells provided by the invention is preserved liquid, and being preferably is human serum albumin (such as the human serum albumin of 0.2-0.4g effective dose or the human serum albumin of 0.4-1.0g effective dose) with the 0.2-1g effective dose, 4.18-4.97g sodium chloride (such as 4.18-4.71g or 4.71-4.97g), 3.99-4.74g gluconic acid sodium salt (such as 3.99-4.49g or 4.49 to 4.74g), 2.90-3.40g sodium acetate (such as 2.90-3.29g or 3.29-3.40g), 0.29-0.35g potassium chloride (such as 0.29-0.33g or 0.33-0.35g), 0.24-0.28g magnesium chloride (such as 0.24-0.27g or 0.27-0.28g) and 0.5-0.7mL heparin calcium inj (such as 0.5-0.6mL or 0.6-0.7mL) water are settled to 100mL and obtain.
Described human serum albumin can add with the form of human serum albumin injection, also can add with the form of human serum albumin freeze-dried powder.
Calciparine has the agglomerating function of the cell aggregation of preventing.
Liver stem cells provided by the invention is preserved liquid and is used for preserving liver stem cells, 12 hours take the inner cell survival rate as more than 85%, even reach more than 95%.
Described liver stem cells is preserved liquid and be can be used for preserving liver stem cells, and the liver stem cells that particularly exsomatizes is preferably stripped people's liver stem cells.
The present invention also protects a kind of method of preserving liver stem cells, is liver stem cells to be suspended in described liver stem cells preserve liquid, preserves below 12 hours for 4-8 ℃ and (preserves 12 hours in 12 hours or 6-8 ℃ such as 4-6 ℃ of preservation); The proportioning that described liver stem cells and described liver stem cells are preserved liquid is 6 * 10
5-7 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid (such as 6 * 10
5-6.8 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid, or 6.8 * 10
5-7 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid).Described liver stem cells can be stripped liver stem cells, is preferably stripped people's liver stem cells.
The present invention also protects a kind of medicine for the treatment of diabetes, is liver stem cells to be suspended in described liver stem cells preserve the cell suspension that liquid obtains; The proportioning that described liver stem cells and described liver stem cells are preserved liquid is 6 * 10
5-7 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid (such as 6 * 10
5-6.8 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid, or 6.8 * 10
5-7 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid).Described liver stem cells can be stripped liver stem cells, is preferably stripped people's liver stem cells.
The medicine for the treatment of diabetes provided by the invention have stability height, good effect, safe, have no side effect, be convenient to store and transport, adapt to clinical extensive use, the characteristics that have a extensive future, the present invention can be the diabetic and brings glad tidings, for new road has been opened up in the use of stem cell clinically.
Medicine provided by the invention can be divided into the liver cell of function, have Regeneration and Repair organa parenchymatosum and the immunoregulatory two-way function of performance, can improve immunologic function, improve liver microenvironment, reduce the inflammatory cytokine secretion, reaction reduces inflammation, can also suppress the generation of Hepatic Stellate Cell Activation, prevention extracellular matrix, all right reverting diabetes, activation oogonium, promotion liver cell regeneration, reparation organa parenchymatosum and Chronic Liver damage.
Embodiment
Following embodiment is convenient to understand better the present invention, but does not limit the present invention.Experimental technique among the following embodiment if no special instructions, is conventional method.Used test material among the following embodiment if no special instructions, is and purchases available from routine biochemistry reagent shop.Quantitative test in following examples all arranges repeated experiments three times, results averaged.
People's liver stem cells document (Human hepatic stem cells): list of references: Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, Moss N, Melhem A, McClelland R, Turner W, Kulik M, Sherwood S, Tallheden T, Cheng N, Furth ME, Reid LM.Human hepaticstem cells from fetal and postnatal donors.J Exp Med.2007,204 (8): 1973-87.
The preparation that embodiment 1, liver stem cells are preserved liquid
Human serum albumin injection is available from Haerbin Shiheng Bioengineering Medicine Stock Co., Ltd., and catalog number is defended the accurate word of medicine (it is prosperous to breathe out generation) S-01 number, every liter of human serum albumin that contains the 20g effective dose for (92).
Heparin calcium inj is available from Sanofi Winthrop Industrie company, and catalog number is J20040119.
Liver stem cells is preserved the preparation method of liquid I: 5mL human serum albumin injection (human serum albumin that contains the 0.1g effective dose), 0.4mL heparin calcium inj, 2.60g sodium chloride, 2.48g gluconic acid sodium salt, 1.82g sodium acetate, 0.18g potassium chloride and 0.15g magnesium chloride water are settled to 100mL.
Liver stem cells is preserved the preparation method of liquid II: 10mL human serum albumin injection (human serum albumin that contains the 0.2g effective dose), 0.5mL heparin calcium inj, 4.18g sodium chloride, 3.99g gluconic acid sodium salt, 2.90g sodium acetate, 0.29g potassium chloride and 0.24g magnesium chloride water are settled to 100mL.
Liver stem cells is preserved the preparation method of liquid III: 20mL human serum albumin injection (human serum albumin that contains the 0.4g effective dose), 0.6mL heparin calcium inj, 4.71g sodium chloride, 4.49g gluconic acid sodium salt, 3.29g sodium acetate, 0.33g potassium chloride and 0.27g magnesium chloride water are settled to 100mL.
Liver stem cells is preserved the preparation method of liquid IV: 50mL human serum albumin injection (human serum albumin that contains the 1g effective dose), 0.7mL heparin calcium inj, 4.97g sodium chloride, 4.74g gluconic acid sodium salt, 3.40g sodium acetate, 0.35g potassium chloride and 0.28g magnesium chloride water are settled to 100mL.
The expansion of the cell of embodiment 2, people's liver stem cells is cultivated
D-hank ' S balanced salt solution buffer solution: solvent is water, contains following solute: 0.8% NaCl, 0.04% KCl, 0.006% Na
2HPO
4H
2O and 0.006% KH
2PO
4% is the quality percentage composition.
1,1 bottle of people's liver stem cells is used twice of 10ml D-hank ' S balanced salt solution buffer solution for cleaning.
2, collecting cell is with digestion under pancreatin 37 ℃ of conditions 6 minutes (5-7 minute all can); In the digestion process under inverted microscope observation of cell, guarantee the catapepsis of people's liver stem cells with palm chucked blake bottle.
3, stop digestion, then add 10ml D-hank ' S balanced salt solution buffer solution in every bottle, piping and druming suspends cell repeatedly, obtains cell suspension.
4, cell suspension is carried out viable count, method is as follows: cell suspension and 0.4% are expected that blue solution equal-volume mixes, gently mixing; After 1 minute, at microscopically blood counting chamber counting cells; Living cells repels platform and expects orchid, and dying blue cell is dead cell.
5, cell suspension is moved in the centrifuge tube, with the centrifugal speed of 900rpm centrifugal 5 seconds, centrifugal end was inhaled and is abandoned supernatant, obtains people's liver stem cells.
The application that the liver stem cells of embodiment 3, embodiment 1 preparation is preserved liquid
Four kinds of liver stem cells that people's liver stem cells among the embodiment 2 are resuspended in respectively embodiment 1 preparation are preserved liquid, and proportioning is 6.8 * 10
5Individual's liver stem cells living cells: the 1ml liver stem cells is preserved liquid, preserves sampling (cell suspension) mensuration cell survival rate after 12 hours for 4 ℃.
Cell survival rate assay method: the 0.5ml cell suspension is expected that with 0.2% of 0.5ml blue solution mixes, and obtains mixed liquor; Draw 10 microlitre mixed liquors, drip at the cover plate edge, mixed liquor is full of between cover plate and the tally; Left standstill 1 minute; Choose at random several visuals field, amount to several 300 cells (counting painted cell number, i.e. the dead cell number), cell survival rate=(300-dead cell number)/300 * 100%; Repeat count 5 times, result are got the mean value of 5 countings.
Carry out altogether repeated experiments three times, results averaged sees Table 1.
The experimental result of table 1 embodiment 3
| The counting cells number | Painted cell number | Cell survival rate % | |
| Liver stem cells is preserved liquid I | 300 | 39±3 | 87.0±1 |
| Liver stem cells is preserved liquid II | 300 | 6±2 | 98±0.7 |
| Liver stem cells is preserved liquid III | 300 | 6±1 | 98.0±0.3 |
| Liver stem cells is preserved liquid IV | 300 | 9±1 | 97.0±0.3 |
Examine under a microscope the gathering situation of cell, cell stability is good, does not assemble agglomerating phenomenon.The result shows: liver stem cells is preserved liquid I, liver stem cells and is preserved liquid II, liver stem cells and preserve liquid III and liver stem cells and preserve liquid IV as preserving liquid, 4 ℃ of depositary's liver stem cells 12 hours, and the survival rate of people's liver stem cells is all more than 86%; Particularly liver stem cells is preserved liquid II, liver stem cells preserves liquid III and liver stem cells is preserved liquid IV, and during as preservation liquid depositary liver stem cells, survival rate is all more than 96%.
The application that the liver stem cells of embodiment 4, embodiment 1 preparation is preserved liquid
Four kinds of liver stem cells that people's liver stem cells among the embodiment 2 are resuspended in respectively embodiment 1 preparation are preserved liquid, and proportioning is 6 * 10
5Individual's liver stem cells living cells: the 1ml liver stem cells is preserved liquid, preserves sampling (cell suspension) mensuration cell survival rate after 12 hours for 6 ℃.
The cell survival rate assay method is with embodiment 3.
Carry out altogether repeated experiments three times, results averaged sees Table 2.
The experimental result of table 2 embodiment 4
| The counting cells number | Painted cell number | Cell survival rate % | |
| Liver stem cells is preserved liquid I | 300 | 34±4 | 89.2±0.3 |
| Liver stem cells is preserved liquid II | 300 | 7±1 | 97.7±0.3 |
| Liver stem cells is preserved liquid III | 300 | 8±1 | 97.7±0.3 |
| Liver stem cells is preserved liquid IV | 300 | 8±1 | 97.0±0.3 |
Examine under a microscope the gathering situation of cell, cell stability is good, does not assemble agglomerating phenomenon.The result shows: liver stem cells is preserved liquid I, liver stem cells and is preserved liquid II, liver stem cells and preserve liquid III and liver stem cells and preserve liquid IV as preserving liquid, 6 ℃ of depositary's liver stem cells 12 hours, and the survival rate of people's liver stem cells is all more than 88%; Particularly liver stem cells is preserved liquid II, liver stem cells preserves liquid III and liver stem cells is preserved liquid IV, and during as preservation liquid depositary liver stem cells, survival rate is all more than 96%.
The application that the liver stem cells of embodiment 5, embodiment 1 preparation is preserved liquid
Four kinds of liver stem cells that people's liver stem cells among the embodiment 2 are resuspended in respectively embodiment 1 preparation are preserved liquid, and proportioning is 7 * 10
5Individual's liver stem cells living cells: the 1ml liver stem cells is preserved liquid, preserves sampling (cell suspension) mensuration cell survival rate after 12 hours for 8 ℃.
The cell survival rate assay method is with embodiment 3.
Carry out altogether repeated experiments three times, results averaged sees Table 3.
The experimental result of table 3 embodiment 5
| The counting cells number | Painted cell number | Cell survival rate % | |
| Liver stem cells is preserved liquid I | 300 | 40±5 | 86.7±0.3 |
| Liver stem cells is preserved liquid II | 300 | 5±1 | 98.3±0.3 |
| Liver stem cells is preserved liquid III | 300 | 7±2 | 97.7±0.3 |
| Liver stem cells is preserved liquid IV | 300 | 10±2 | 96.7±0.7 |
Examine under a microscope the gathering situation of cell, cell stability is good, does not assemble agglomerating phenomenon.The result shows: liver stem cells is preserved liquid I, liver stem cells and is preserved liquid II, liver stem cells and preserve liquid III and liver stem cells and preserve liquid IV as preserving liquid, 8 ℃ of depositary's liver stem cells 12 hours, and the survival rate of people's liver stem cells is all more than 86%; Particularly liver stem cells is preserved liquid II, and during as preservation liquid depositary liver stem cells, survival rate is all more than 96%.
Because the known effect with treatment diabetes of liver stem cells, so being resuspended in liver stem cells provided by the invention, liver stem cells preserves liquid, can obtain a kind of medicine for the treatment of diabetes, the medicine of these treatment diabetes need to be under 4-8 ℃ of lucifuge environment storage and transport, the term of validity is 12 hours.The medicine of these treatment diabetes is applicable to venoclysis, calculates by weight in patients kilogram number, and recommending consumption is 0.5 * 10
6-1 * 10
6Individual's liver stem cells living cells/kg body weight.
Claims (10)
1. a liver stem cells is preserved liquid, is that human serum albumin, 2.60-4.97g sodium chloride, 2.48-4.74g gluconic acid sodium salt, 1.82-3.40g sodium acetate, 0.18-0.35g potassium chloride, 0.15-0.28g magnesium chloride and 0.4-0.7mL heparin calcium inj water with the 0.1-1g effective dose is settled to 100mL and obtains.
2. liver stem cells as claimed in claim 1 is preserved liquid, it is characterized in that: it is that human serum albumin, 4.18-4.97g sodium chloride, 3.99-4.74g gluconic acid sodium salt, 2.90-3.40g sodium acetate, 0.29-0.35g potassium chloride, 0.24-0.28g magnesium chloride and 0.5-0.7mL heparin calcium inj water with the 0.2-1g effective dose is settled to 100mL and obtains that described liver stem cells is preserved liquid.
3. claim 1 or 2 described liver stem cells are preserved the application of liquid in preserving liver stem cells.
4. application as claimed in claim 3 is characterized in that: the liver stem cells of described liver stem cells for exsomatizing.
5. such as claim 3 or 4 described application, it is characterized in that: described liver stem cells behaviour liver stem cells.
6. a method of preserving liver stem cells is that liver stem cells is suspended in claim 1 or 2 described liver stem cells preservation liquid, preserves below 12 hours for 4-8 ℃; The proportioning that described liver stem cells and described liver stem cells are preserved liquid is 6 * 10
5-7 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid.
7. method as claimed in claim 6 is characterized in that: the liver stem cells of described liver stem cells for exsomatizing.
8. such as claim 6 or 7 described methods, it is characterized in that: described liver stem cells behaviour liver stem cells.
9. medicine for the treatment of diabetes is liver stem cells to be suspended in claim 1 or 2 described liver stem cells are preserved the cell suspension that liquid obtain; The proportioning that described liver stem cells and described liver stem cells are preserved liquid is 6 * 10
5-7 * 10
5Individual liver stem cells living cells: the 1mL liver stem cells is preserved liquid.
10. medicine as claimed in claim 9 is characterized in that: the liver stem cells of described liver stem cells for exsomatizing is preferably stripped people's liver stem cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110251598.8A CN102948413B (en) | 2011-08-29 | 2011-08-29 | Hepatic stem cell preserving solution and applications of hepatic stem cell preserving solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110251598.8A CN102948413B (en) | 2011-08-29 | 2011-08-29 | Hepatic stem cell preserving solution and applications of hepatic stem cell preserving solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102948413A true CN102948413A (en) | 2013-03-06 |
| CN102948413B CN102948413B (en) | 2014-09-03 |
Family
ID=47758241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110251598.8A Active CN102948413B (en) | 2011-08-29 | 2011-08-29 | Hepatic stem cell preserving solution and applications of hepatic stem cell preserving solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102948413B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103404509A (en) * | 2013-08-07 | 2013-11-27 | 彭乐 | Cell preserving fluid as well as preparation method and application of cell preserving fluid |
| CN104388383A (en) * | 2014-08-29 | 2015-03-04 | 中国人民解放军第二军医大学 | Long-term in-vitro culture and directional differentiation system and method for liver stem cell |
| CN104920340A (en) * | 2015-07-15 | 2015-09-23 | 广州赛莱拉干细胞科技股份有限公司 | Immune cell preserving fluid and application thereof |
| CN104996396A (en) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | Perfusion preservation fluid for isolated liver |
| CN105052895A (en) * | 2015-09-01 | 2015-11-18 | 广州赛莱拉干细胞科技股份有限公司 | LAK cell preservation solution, preparation method thereof and LAK cell preservation method |
| CN106474157A (en) * | 2015-10-14 | 2017-03-08 | 北京昱龙盛世生物科技有限公司 | A kind of liver stem cells injection and preparation method thereof |
| CN107970258A (en) * | 2017-11-20 | 2018-05-01 | 英普乐孚生物技术(上海)有限公司 | A kind of Chimeric antigen receptor T cell preparation |
| WO2018113796A1 (en) * | 2016-12-23 | 2018-06-28 | 西比曼生物科技（上海）有限公司 | Cell freezing medium for clinical use |
| CN110583625A (en) * | 2019-09-17 | 2019-12-20 | 深圳大学 | Umbilical cord storage liquid |
| CN113498779A (en) * | 2021-04-22 | 2021-10-15 | 重庆医科大学附属儿童医院 | Reagent and method for transporting cells |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177116A1 (en) * | 1996-06-14 | 2002-11-28 | Biostore New Zealand Ltd. | Compositions and methods for the preservation of living tissues |
| CN101210232A (en) * | 2006-12-28 | 2008-07-02 | 天津昂赛细胞基因工程有限公司 | Mesenchyme stem cell preserving fluid and use thereof |
| CN101474145A (en) * | 2008-11-11 | 2009-07-08 | 沈七襄 | Compound sodium acetate injection |
| CN101851605A (en) * | 2010-04-29 | 2010-10-06 | 北京弘润天源生物技术有限公司 | Selective medium of liver stem cells, method for selectively separating and amplifying liver stem cells as well as medicinal composition for treating diabetes |
| CN102008507A (en) * | 2010-11-21 | 2011-04-13 | 天津和泽干细胞科技有限公司 | Human umbilical cord mesenchymal stem cell (HUMSC) anti-hepatic fibrosis injection and preparation method thereof |
-
2011
- 2011-08-29 CN CN201110251598.8A patent/CN102948413B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177116A1 (en) * | 1996-06-14 | 2002-11-28 | Biostore New Zealand Ltd. | Compositions and methods for the preservation of living tissues |
| CN101210232A (en) * | 2006-12-28 | 2008-07-02 | 天津昂赛细胞基因工程有限公司 | Mesenchyme stem cell preserving fluid and use thereof |
| CN101474145A (en) * | 2008-11-11 | 2009-07-08 | 沈七襄 | Compound sodium acetate injection |
| CN101851605A (en) * | 2010-04-29 | 2010-10-06 | 北京弘润天源生物技术有限公司 | Selective medium of liver stem cells, method for selectively separating and amplifying liver stem cells as well as medicinal composition for treating diabetes |
| CN102008507A (en) * | 2010-11-21 | 2011-04-13 | 天津和泽干细胞科技有限公司 | Human umbilical cord mesenchymal stem cell (HUMSC) anti-hepatic fibrosis injection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| JACOB HANNA 等: "Preservation of stem cells", 《ORGANOGENESIS》, vol. 5, no. 3, 30 September 2009 (2009-09-30) * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103404509B (en) * | 2013-08-07 | 2015-04-08 | 彭乐 | Cell preserving fluid as well as preparation method and application of cell preserving fluid |
| CN103404509A (en) * | 2013-08-07 | 2013-11-27 | 彭乐 | Cell preserving fluid as well as preparation method and application of cell preserving fluid |
| CN104388383B (en) * | 2014-08-29 | 2017-05-24 | 中国人民解放军第二军医大学 | Long-term in-vitro culture and directional differentiation system and method for liver stem cell |
| CN104388383A (en) * | 2014-08-29 | 2015-03-04 | 中国人民解放军第二军医大学 | Long-term in-vitro culture and directional differentiation system and method for liver stem cell |
| CN104920340A (en) * | 2015-07-15 | 2015-09-23 | 广州赛莱拉干细胞科技股份有限公司 | Immune cell preserving fluid and application thereof |
| CN104996396A (en) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | Perfusion preservation fluid for isolated liver |
| CN104996396B (en) * | 2015-07-27 | 2016-10-05 | 中山大学附属第一医院 | A kind of preservative fluid for perfusing extracorporeal liver |
| CN105052895A (en) * | 2015-09-01 | 2015-11-18 | 广州赛莱拉干细胞科技股份有限公司 | LAK cell preservation solution, preparation method thereof and LAK cell preservation method |
| CN106474157A (en) * | 2015-10-14 | 2017-03-08 | 北京昱龙盛世生物科技有限公司 | A kind of liver stem cells injection and preparation method thereof |
| WO2018113796A1 (en) * | 2016-12-23 | 2018-06-28 | 西比曼生物科技（上海）有限公司 | Cell freezing medium for clinical use |
| CN108235981A (en) * | 2016-12-23 | 2018-07-03 | 西比曼生物科技（上海）有限公司 | It is a kind of can Clinical practice cells frozen storing liquid |
| CN108235981B (en) * | 2016-12-23 | 2021-07-23 | 西比曼生物科技（香港）有限公司 | Cell cryopreservation liquid capable of being used clinically |
| US11363812B2 (en) | 2016-12-23 | 2022-06-21 | Cellular Biomedicine Group Hk Limited | Cell freezing medium for clinical use |
| CN107970258A (en) * | 2017-11-20 | 2018-05-01 | 英普乐孚生物技术(上海)有限公司 | A kind of Chimeric antigen receptor T cell preparation |
| CN107970258B (en) * | 2017-11-20 | 2020-11-10 | 英普乐孚生物技术(上海)有限公司 | Chimeric antigen receptor T cell preparation |
| CN110583625A (en) * | 2019-09-17 | 2019-12-20 | 深圳大学 | Umbilical cord storage liquid |
| CN113498779A (en) * | 2021-04-22 | 2021-10-15 | 重庆医科大学附属儿童医院 | Reagent and method for transporting cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102948413B (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102948413B (en) | Hepatic stem cell preserving solution and applications of hepatic stem cell preserving solution | |
| Markmann et al. | Insulin independence following isolated islet transplantation and single islet infusions | |
| Ciccocioppo et al. | Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease | |
| Peng et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study | |
| Guan et al. | Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes | |
| Turbeville et al. | Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI | |
| US20120201791A1 (en) | Methods of treating diseases or conditions using mesenchymal stem cells | |
| Marfe et al. | Blood derived stem cells: an ameliorative therapy in veterinary ophthalmology | |
| Zhou et al. | Hydrogen inhalation decreases lung graft injury in brain-dead donor rats | |
| KR101160198B1 (en) | Method of separating pancreatic islet | |
| JP2018538328A (en) | Composition comprising ginseng saponin as an active ingredient | |
| RU2013140543A (en) | PLURIPOTENT STEM CELLS AND METHOD OF STIMULATION AND ISOLATION OF NON-EMBRYONAL PLURIPOTENT STEM CELLS FROM MAMMAL BLOOD AND APPLICATION OF DILATED PLURIPOTENT STEM CELLS | |
| Zheng et al. | Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NFκB, Egr1, Nrf2, MAPKs and PI3K signals | |
| CA3106188A1 (en) | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria | |
| Hatakeyama et al. | Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation: a single-center experience | |
| Lemarie et al. | Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate | |
| Tang et al. | Mesenchymal stem cells and their small extracellular vesicles as crucial immunological efficacy for hepatic diseases | |
| Ismail et al. | The effect of in vivo mobilization of bone marrow stem cells on the pancreas of diabetic albino rats (a histological & immunohistochemical study) | |
| Jennette et al. | Pathogenesis of vasculitis | |
| Shindo et al. | Total pancreatectomy with islet autotransplantation: recent updates and outcomes | |
| Han et al. | Immunomodulatory effect of Lycium barbarum polysaccharides against liver fibrosis based on the intelligent medical internet of things | |
| Zaidman et al. | Allogeneic stem cell transplantation in congenital hemoglobinopathies using a tailored busulfan-based conditioning regimen: single-center experience | |
| JP4709552B2 (en) | LFA-1 inhibitor and use thereof | |
| El-Sawah et al. | Investigation of the antioxidant defensive role of both AD-MSCs and BM-MSCs in modulating the alteration in the oxidative stress status in various STZ-diabetic rats’ tissues | |
| AU2017241626B2 (en) | Viable cell compositions, and methods related to same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |